What is ATYR's market cap?

$15.07M, based on the Nov 5 close of $6.03.

Does aTyr Pharma pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ATYR is sold short?

10.3M shares, 10.5% of float, as of Oct 15, 2026.

What sector is ATYR in?

Healthcare, in the Biotechnology industry.

NASDAQ · ATYRHealthcareBiotechnology

aTyr Pharma, Inc. Common Stock (ATYR)

$6.03−2.43%

Close Nov 5, 2026 · split-adjusted

Nov 5, 2026$6.03▼ 81.48% in range

Nov 5, 2025Low $4.94 · High $205.44Nov 5, 2026

What changed · written from our data

As of Nov 5, 2026

aTyr Pharma closed at $6.03 on Nov 5, down 2.43%, 97.1% below its 52-week closing high. Volume of 61.5K shares was 0.04× its 20-day average (below normal).

Split-adjusted performance: -45.8% over one month, -83.6% over six months, -81.8% over one year.

Short interest was 10.3M shares at the Oct 15 settlement, down 20.3% from the prior report (10.5% of float, 5.4 days to cover).

Market cap$15.1M2.5M shares

Revenue · quarter$0.00—

Diluted EPS$-4.40—

P/E · TTM—P/S 79.3×

Net margin—

Dividend yieldNone

52-week range4.94 – 205.44−97.1% from high

Volume61.5K0.04× 20-day avg

Volatility · 60d1,072.3%Annualised

Short % of float10.5%5.4 days to cover

Net cash$56.9MCash $57.4M

Next earnings—Not scheduled

Split-adjusted performance

1W +12.3%1M −45.8%3M −70.5%6M −83.6%YTD −80.7%1Y −81.8%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum4

Revenue growth—

Net margin—

Value (low P/E)—

Size12

Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.

Short interest

Details →

Shares short10.3M−20.3% vs prior

Days to cover5.4Settled Oct 15

% of float10.5%

Short vol. 10d57.5%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ATYRaTyr Pharma	$6.03	−2.43%	−83.6%	—	—	—	$15.1M
ABOSAcumen Pharmaceuticals	$0.2138	−1.16%	−91.3%	—	—	—	$15.5M	Compare
JSPRJasper Therapeutics	$0.4692	−8.20%	−48.3%	—	—	—	$15.6M	Compare
PLURPluri	$1.19	−3.26%	−64.4%	−15.8%	−1755.2%	—	$16.1M	Compare
DYAIDyadic International	$0.3401	−7.25%	−54.3%	−0.6%	−221.0%	—	$13.6M	Compare
BCDABioCardia	$0.8900	−2.53%	−18.3%	—	—	—	$13.5M	Compare
ESLAEstrella Immunopharma	$0.4101	−7.53%	−67.7%	—	—	—	$17.8M	Compare
TCRXTScan Therapeutics	$0.1818	−13.43%	−85.0%	−65.8%	−2888.6%	—	$12.3M	Compare
BKHABlack Hawk Acquisition	$4.50	−19.21%	—	—	—	—	$18.7M	Compare

News about aTyr Pharma

All news →

aTyr Pharma Announces One-for-40 Reverse Stock SplitGlobeNewswire Inc. · Oct 27, 2026▼ Negative aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate UpdateGlobeNewswire Inc. · May 15, 2026▲ Positive

Quick answers

What does aTyr Pharma do?: aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets.
What is ATYR's market cap?: $15.07M, based on the Nov 5 close of $6.03.
Does aTyr Pharma pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ATYR is sold short?: 10.3M shares, 10.5% of float, as of Oct 15, 2026.
What sector is ATYR in?: Healthcare, in the Biotechnology industry.

About aTyr Pharma

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

HQ: San Diego, CA58 employeesListed May 7, 2015atyrpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology